Search Results

You are looking at 81 - 90 of 403 items for :

  • "bevacizumab" x
  • Refine by Access: All x
Clear All
Full access

Targeted Strategies in the Treatment of Metastatic Colon Cancer

Diane Reidy and Leonard Saltz

R . Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naíve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704 [abstract] . J

Full access

Selecting Targeted Therapies for Patients With Renal Cell Carcinoma

Elizabeth R. Plimack and Gary R. Hudes

endothelial growth factor (VEGF)-directed therapies (sorafenib, sunitinib, pazopanib, and bevacizumab) and mammalian target of rapamycin (mTOR) inhibitors (temsirolimus and everolimus). With such a large number of treatment options, selecting among them for a

Full access

Colon Cancer: The New Chronic Disease

Al B. Benson III

(Panitumumab Efficacy in Combination With mFOLFOX6 Against Bevacizumab plus mFOLFOX6 in Metastatic CRC Subjects With Wild-Type KRAS Tumors), were further assessed in secondary analyses to include extended RAS testing ( KRAS exons 2, 3, 4; NRAS exons 2, 3

Full access

Maintenance Chemotherapy in Non–Small Cell Lung Cancer

Keith D. Eaton and Renato G. Martins

growth factor receptor (EGFR) to chemotherapy, 7 and the incorporation of other non-chemotherapy agents 8 all failed to improve survival and QOL. Recently, the addition of the anti–vascular endothelial growth factor (VEGF) antibody bevacizumab

Full access

Management of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

Presented by: Joyce F. Liu

benefit from bevacizumab? Is testing for homologous recombination deficiency (HRD)/genomic instability appropriate? What is the role of maintenance therapy with PARP inhibitors? Of note, because the treatment of advanced ovarian cancer is complex and

Full access

Oncology Research Program

Carboplatin Followed By Doxorubicin Plus Cyclophosphamide With Bevacizumab Added Concurrently to Chemotherapy for Palpable and Operable Triple Negative Invasive Breast Cancer Principal Investigator: Jasgit C. Sachdev, MD Condition: Triple negative breast

Full access

Oncology Research Program

Bevacizumab Added Concurrently to Chemotherapy for Palpable and Operable Triple-Negative Invasive Breast Cancer Principal Investigator: Jasgit C. Sachdev, MD Condition: Triple-negative breast cancer Institutions: University of Tennessee Cancer

Full access

Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology

Al B. Benson III, Alan P. Venook, Mohamed Adam, George Chang, Yi-Jen Chen, Kristen K. Ciombor, Stacey A. Cohen, Harry S. Cooper, Dustin Deming, Ignacio Garrido-Laguna, Jean L. Grem, Paul Haste, J. Randolph Hecht, Sarah Hoffe, Steven Hunt, Hisham Hussan, Kimberly L. Johung, Nora Joseph, Natalie Kirilcuk, Smitha Krishnamurthi, Midhun Malla, Jennifer K. Maratt, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna Parikh, Hitendra Patel, Katrina Pedersen, Leonard Saltz, Charles Schneider, David Shibata, Benjamin Shogan, John M. Skibber, Constantinos T. Sofocleous, Anna Tavakkoli, Christopher G. Willett, Christina Wu, Lisa A. Gurski, Jenna Snedeker, and Frankie Jones

analysis of the FIRE-3 trial (discussed in “ Cetuximab or Panitumumab Versus Bevacizumab in First-line Therapy ,”) has been published. 30 When all RAS ( KRAS/NRAS ) mutations were considered, PFS was significantly worse in patients with RAS -mutant

Full access

HSR22-145: Pembrolizumab Plus Chemotherapy for First-Line Treatment of Advanced Triple-Negative Breast Cancer – A Network Meta-Analysis

Amin Haiderali, Min Huang, Wilbur Pan, Grace Fox, Dylan Maciel, and Andrew Frederickson

nab-paclitaxel for PFS. Statistical superiority was also reported for pembrolizumab+paclitaxel compared to paclitaxel (for OS and PFS), paclitaxel+ bevacizumab (for OS) and ixabepilone+bevacizumab (for OS). Conclusions : These analyses suggest

Full access

HSR21-065: Oncologists’ Perceptions and Utilization of Therapeutic Oncology Biosimilars in the U.S.

Sonia Oskouei, Amy Graham Russell, Yolaine Jeune-Smith, and Ajeet Gajra

critical therapies with the potential to lower cost of care. There are 9 FDA approved therapeutic oncology biosimilars to 3 reference molecules: trastuzumab (5), bevacizumab (2) and rituximab (2), in addition to supportive care biosimilars for hematopoietic